About the Company
Neuralstem Inc. is a biotechnology company headquartered in Rockville, Maryland that specializes in developing commercial-scale production of multiple types of central nervous system stem cells. In October 2019 Neuralstem announces that the company has changed its name to Seneca Biopharma, Inc. In April 2021 Seneca Biopharma merged with Leading BioSciences to form the combined company Palisade Bio, Inc.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on PALISADE BIO, INC.
Palisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative Colitis
Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide ...
Carlsbad, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic ...
Palisade Bio, Inc. Closes $5 Million Underwritten Public ... - Nasdaq
Palisade Bio closed a $5 million public offering to fund clinical trials and research for autoimmune and inflammatory diseases. Quiver AI Summary Palisade Bio, Inc. has successfully closed an ...
Palisade Bio, Inc. Appoints Dr. Emil Chuang to Board of ... - Nasdaq
Palisade Bio, Inc. Appoints Dr. Emil Chuang to Board of Directors to Enhance Clinical Strategy for Fibrostenotic Crohn's Disease and Ulcerative Colitis July 09, 2025 — 08:50 am EDT ...
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
– Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade ...
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ...
Upgrade Now Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference Palisade Bio, Inc. Wed, Feb 19, 2025, 9:00 AM4 min read In This Article: PALI ...
Palisade Bio’s stock more than doubles on news of ... - MarketWatch
Palisade Bio Inc.’s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade ...
Palisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for ...
Aktien»Nachrichten»PALISADE BIO AKTIE» PALISADE BIO INC WKN: A4098S|ISIN: US6963894026|Ticker-Symbol: 7NS0 NASDAQ 02.07.25 | 16:44 0,750US-Dollar 0,00 % 0,000 Branche Biotechnologie Aktienmarkt ...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides ...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook Nov. 10, 2023 8:05 AM ET Palisade Bio, Inc. (PALI) ...
PALI - Palisade Bio Inc Chart | Morningstar
Palisade Bio Inc PALI Stock XNAS Rating as of Oct 8, 2024 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating Performance Dividends ...
PALI - Palisade Bio Inc Trailing Returns | Morningstar
Stay up to date on how Palisade Bio Inc (PALI:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide ...
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel ...
Similar Companies
Loading the latest forecasts...